CCI approves proposed combination involving acquisition of 20% of the issued and paid-up equity share capital of Piramal Pharma Limited (Pharma Co.) by CA Clover Intermediate II Investments (Curie)

CCI approves proposed combination involving acquisition of 20% of the issued and paid-up equity share capital of Piramal Pharma Limited (Pharma Co.) by CA Clover Intermediate II Investments (Curie) https://www.taxtmi.com/news?id=23129 The Competition Commission approved a proposed combination in which Piramal Enterprises transfers its global pharmaceutical business into wholly owned Piramal Pharma Limited, followed by a minority equity acquisition in that subsidiary by CA Clover Intermediate II Investments, combining an intra group business carve out with a third party investment in the carved out operating entity covering CDMO, Complex Hospital Generics and Consumer Healthcare segments. en-us Sat, 12 Sep 2020 11:25:55 +0530 Sat, 12 Sep 2020 11:25:55 +0530 TaxTMI RSS Generator CCI approves proposed combination involving acquisition of 20% of the issued and paid-up equity share capital of Piramal Pharma Limited (Pharma Co.) by CA Clover Intermediate II Investments (Curie) https://www.taxtmi.com/news?id=23129 The Competition Commission approved a proposed combination in which Piramal Enterprises transfers its global pharmaceutical business into wholly owned Piramal Pharma Limited, followed by a minority equity acquisition in that subsidiary by CA Clover Intermediate II Investments, combining an intra group business carve out with a third party investment in the carved out operating entity covering CDMO, Complex Hospital Generics and Consumer Healthcare segments. News - Sat, 12 Sep 2020 11:25:55 +0530 https://www.taxtmi.com/news?id=23129